



Press release from Emotra AB (publ)
Göteborg, March 17, 2014

Co-operation agreement with two more clinics

Emotra has signed co-operation agreement with two more clinical teams, with one clinic from Oviedo in Spain and with one from Rome in Italy. The Rome clinic is the second Rome based clinic that will participate in the study. The team from Rome will be managed by Prof. Marco Sarchiapone, who also holds a position as a scientific advisor to Emotra. These are the fifteenth and sixteenth clinical centres that have signed agreements to participate in clinical multi-centre study for the purpose of evaluating the use of EDOR to assess potential suicide risks.

So far, sixteen clinics have signed co-operation agreements with Emotra. The Company has earlier aimed to involve 15 European clinical centres in the clinical trials of Emotra's testing method, EDOR. We expect these trials to continue over the next two years. Discussions and negotiations are ongoing with other clinics. The product is now CE marked. A training & education/start up meeting will be held as soon as it is possible to gather most of the clinical teams that will participate in the study. The individual clinics involved will be able to start testing patients as soon as their respective ethical committees have given the green light.

At present, Emotra is in the middle of a very dynamic phase involving an increasing number of clinical centres. In order to minimise the financial risks, all work is carried out within a small organisation and as cost-effectively as possible. When international, scientific support for EDOR from these clinics has grown sufficiently strong, we will launch the method in Europe.

For further information, please contact:

Claes Holmberg, CEO
Telephone: +46 708 25 45 47
E-mail: claes@emotra.se

Lars-Håkan Thorell, Head of Research
Telephone: +46 733 95 31 20
E-mail: lars@emotra.se

Emotra AB is listed on AktieTorget, and the Company has developed a method – EDOR – of detecting depressed patients who are at risk of committing suicide. Altogether, more than 1,000 patients have been tested and followed up. EDOR has shown a reliability rate of up to 97%. In other words, Emotra's method can determine, with 97% certainty, if a person runs a significantly higher risk of suicide attempt, facilitating decisions about where special suicide prevention measures are needed. EDOR helps the right patients get the care they need.